Noemi Stefanía CsabaView profile
Professor
Noemi Stefanía Csaba is a Professor at the University of Santiago de Compostela, affiliated with the Department of Pharmacology, Pharmacy and Pharmaceutical Technology within the Faculty of Pharmacy. She is also part of the Center for Research in Molecular Medicine and Chronic Diseases (CIMUS). Her research focuses on nanotechnologies applied to drug delivery systems, particularly in the development of gene therapy carriers, vaccines, and targeted therapies for cancer and infectious diseases. She earned her PhD in 2005 with a thesis on genetic vaccine delivery systems under the supervision of Dr. María José Alonso Fernández and Dr. Alejandro Sánchez Barreiro. Her research interests encompass nanomedicine, biomaterials engineering, and mucosal drug delivery. She has pioneered studies on protamine nanocapsules, chitosan-based systems, and polyphosphazene derivatives for targeted drug delivery. Her work addresses challenges in overcoming biological barriers (e.g., nasal-to-brain, pulmonary, intestinal) and enhancing therapeutic efficacy through nanoparticle design. Notable contributions include the development of semisynthetic pneumococcal nanovaccines, hybrid peptide-polymer platforms for cancer immunotherapy, and lymphatic-targeted anticancer nanocarriers. Her articles highlight advancements in gene delivery for glioblastoma, ocular tumor treatment, and macrophage-targeted pulmonary therapies. While no specific awards are listed, her prolific publication record (spanning 2002–2025) reflects sustained innovation in pharmaceutical nanotechnology. She collaborates widely on projects integrating biomaterials, molecular medicine, and translational drug delivery systems. Her lab (NANOBIOFAR research group) focuses on translational nanomedicine, emphasizing practical applications such as ready-to-use dry powders for pulmonary delivery and plant-derived sporopollenin microcapsules for drug encapsulation. Current work includes optimizing nanoparticle stability, improving vaccine adjuvants, and addressing barriers in intestinal and transmucosal drug absorption.






